Crossmark

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

Crossref DOI link: https://doi.org/10.1186/s12879-019-3974-7

Published Online: 2019-05-03

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maughan, A.

Sadigh, K.

Angulo-Diaz, V.

Mandimika, C.

Villanueva, M.

Lim, J. K.

Ogbuagu, O. https://orcid.org/0000-0001-7342-2608
License Information

Text and Data Mining valid from 2019-05-03
More Information

Article History

Received: 23 October 2018

Accepted: 11 April 2019

First Online: 3 May 2019

Ethics approval and consent to participate

: Study was approved by Yale University Human Investigations Committee (approval number 1401013228). As this was a cross-sectional study based on review of medical records only, informed consent for participants was waived by the committee.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.